Nomogram Developed to Guide Management of Thin Melanomas
Using readily available clinicopathologic information, a team of investigators developed a risk calculator to predict disease recurrence in patients with thin melanomas.
Skin Cancer News
SKIN CANCER ADVISOR
Skin Cancer News
Cavrotolimod Designated Orphan Drug for Merkel Cell Carcinoma
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
Detection of ctDNA Predicts Clinical Outcome in BRAFV600 Melanoma
A team of researchers assessed the relationship between BRAFV600-mutant ctDNA in plasma samples and outcomes in patients with BRAFV600 mutation-positive melanoma.
Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma
FMT plus anti-PD-1 therapy may change gut microbiome and help overcome drug resistance in some patients with advanced melanoma.
Socioeconomic, Education Factors Contribute to Worse Survival in People of African Descent With Skin Cancer
The differences in incidence, clinical features, genetics, treatment and outcome, in cutaneous melanoma in White vs people of African descent populations is reviewed.
FDA Approves Libtayo for Locally Advanced and Metastatic Basal Cell Carcinoma
The FDA has approved Libtayo for the treatment of patients with locally advanced and metastatic basal cell carcinoma (laBCC) who have previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate
5 Skin Cancer Risk Factors During Winter
Patients may neglect their skin health when the weather gets cold, but they remain at risk of damaging their skin and developing cancer in the winter, too. What winter-specific risk factors can clinicians discuss with patients?
Preliminary Evidence Suggests Feasibility of Early Immunotherapy Cessation in Metastatic Melanoma
Investigators reviewed the clinical outcomes of patients with metastatic melanoma who electively discontinued PD-1 inhibitor therapy at 1 year.
Association of UV Exposure and Melanoma Is Weak in Individuals With Skin of Color
Investigators assessed and synthesized existing data on the association of UV exposure and the risk for cutaneous melanoma in individuals with skin of color.
Black Patients With Merkel Cell Carcinoma Experience Treatment Delays
Factors associated with delays in treatment for patients with Merkel cell carcinoma were investigated.
T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
Reflectance Confocal Microscopy vs Biopsy for Diagnosis of Basal Cell Carcinoma
The sensitivity of reflectance confocal microscopy is evaluated in the context of basal cell carcinoma diagnosis.
A Statistical Fallacy Might Mar Study Findings on Bevacizumab in Melanoma
“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
G-CSF Pretreatment Ameliorates the Activity of an Autologous DC-Based Vaccine in Melanoma
Pretreatment with G-CSF prior to receiving an autologous DC-based vaccine resulted in worse outcomes compared with no G-CSF, according to results of a phase 2b study.
Effects of Drugs Targeting Mitochondrial Respiration in Melanoma
Despite relying on glycolysis, there is growing evidence that many tumor types still have high levels of mitochondrial energy metabolism and functioning oxidative phosphorylation. One such subset of tumors is melanoma, potentially playing a role in both tumor progression and resistance to therapy. This has led researchers to wonder whether targeting mitochondrial respiration could be…
Neoadjuvant CMP-001 Plus Nivolumab Found Active in Stage III Melanoma
Neoadjuvant CMP-001 plus nivolumab demonstrated antitumor activity and upregulated the intratumor immune response in patients with stage III melanoma.
BEMPEG Plus Nivolumab Induces Durable Responses in Metastatic Melanoma
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
Risk of Melanoma Measured in Mutation Burden of Skin Cells
Mutation count could offer personal screening guidelines.
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?
Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Skin Cancer
